Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis

In 215 patients with a median age of 16 years, fingolimod was superior to interferon beta-1a in reducing relapses of multiple sclerosis and the accumulation of new lesions on MRI over a 2-year period. Seizures occurred in 5.6% of patients in the fingolimod group.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine Jg. 379; H. 11; S. 1017 - 1027
Hauptverfasser:	Chitnis, Tanuja, Arnold, Douglas L, Banwell, Brenda, Brück, Wolfgang, Ghezzi, Angelo, Giovannoni, Gavin, Greenberg, Benjamin, Krupp, Lauren, Rostásy, Kevin, Tardieu, Marc, Waubant, Emmanuelle, Wolinsky, Jerry S, Bar-Or, Amit, Stites, Tracy, Chen, Yu, Putzki, Norman, Merschhemke, Martin, Gärtner, Jutta
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Massachusetts Medical Society 13.09.2018
Schlagworte:	Adults Age Body weight Clinical trials Convulsions FDA approval Interferon Leukopenia Life Sciences Magnetic resonance imaging Multiple sclerosis NMR Nuclear magnetic resonance Patients Pediatrics Regulatory approval Tachycardia Technical communication β-Interferon Headache Immunologic Factors Brain Administration Relapsing-Remitting Interferon-beta Leukopenia Humans Fingolimod Hydrochloride Male Secondary Prevention Oral Intramuscular Multiple Sclerosis Infection Magnetic Resonance Imaging Injections Adolescent Female Child
ISSN:	0028-4793, 1533-4406, 1533-4406
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In 215 patients with a median age of 16 years, fingolimod was superior to interferon beta-1a in reducing relapses of multiple sclerosis and the accumulation of new lesions on MRI over a 2-year period. Seizures occurred in 5.6% of patients in the fingolimod group.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1800149